Effect of weight loss on the course of non-alcoholic fatty liver disease: results of 6-month follow-up

Aim of investigation. To study the effect of nonpharmaceutical correction of body weight on the level of
high cardio-vascular risk markers at non-alcoholic fatty liver disease (NAFLD).
Material and methods. Overall 117 patients with NAFLD at steatosis stage combined to obesity or metabolic syndrome (MS) — 59 and 58 patents respectively, mean age 43 years (38 to 46 years) and 45 years (39- 49) were investigated. Levels of lipid and carbohydrate metabolism markers, TNF-α, leptin, adiponectin and nitric oxide (NO) metabolites were evaluated.
Results. Weight loss for at least 5% was gained in 44,1% of patients with NAFLD in association to obesity
and in 56,6% of those with NAFLD in combination to MS, that was accompanied by significant reduction of lipid atherogenic fraction levels (cholesterol, low density lipoproteins), decrease of insulin resistance index, CRP and TNF-α inflammation markers, and decrease of leptin concentration in MS group. Comparative analysis of adiponectin and NO metabolites concentration has shown demonstrated, that in patients with NAFLD both in combination to obesity, and in combination to MS the target level of weight loss is accompanied by elevation of adiponectin level (р<0,05) and NO stable metabolites (р<0,05), whereas concentration of nitrites is increased significantly (р<0,05) only in obese patients.
Conclusions. Weight loss for 5% and over at steatosis stage of NAFLD is characterized by decrease of
biochemical cardio-vascular risk markers, in addition the group with 40 min/day physical exercises inefficacy had lower level of insulin resistance index and TNF-α along with higher levels of NO metabolites.

1. Ройтберг Г. Е., Шархун О. О., Платонова О. Е., Ушакова Т. И. Неалкогольная жировая болезнь печени как фактор риска атеросклероза. Экспер клин гастроэнтерол 2010; 7:20-4.

2. Argo C. K., Northup P. G., Al-Osaimi A.M., Caldwell S. H. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51:371-9.

3. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008; 51:1947-53.

4. Ekstedt M., Franzén L. E., Mathiesen U. L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865-73.

5. Кособян Е. П., Смирнова О. М. Современные концепции патогенеза неалкогольной жировой болезни печени. Сахарный диабет 2010; 1:55-64.

6. Ивашкин В. Т., Драпкина О. М., Шульпекова Ю. О. Диагностика и лечение неалкогольной жировой болезни печени. Рос мед вести 2009; 3(14):1-12.

7. Matteoni C., Younossi Z. M., Gramlich T. Nonalcogolic fatty liver disease: А spectrum of clinical pathological severity. Gastroenterology 2009; 116:1413-9.

8. Ratziu V., Bellentani S., Cortez-Pinto H., Day C. P., Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 Special Conference. J Hepatol 2010; 53:372-84.

9. Чеснокова Л. В., Петров И. М., Трошина И. А., Медведева И. В. Содержание провоспалительных цитокинов в зависимости от стадии фиброза у больных с метаболическим синдромом и неалкогольной жировой болезнью печени. Клин мед 2013; 12(91):34-8.

10. Mousavinasab F., Tahtinen T., Jokelainen J., et al. Lack of increase of serum adiponectin concentrations with a moderate weight loss during six months on a high-caloric diet in military service among a young male Finnish population. Endocrine 2005; 26:65-9.

11. Петров И. М., Шоломов И. Ф., Медведева И. В. Трехлетняя эффективность обучения больных с высоким сердечно-сосудистым риском в условиях организованной популяции промышленного города Крайнего Севера. Ожирение и метаболизм 2013; 3:37-43.

12. Chang L. C., Huang K. C., Wu Y. W., et al. The clinical implications of blood adiponectin in cardiometabolic disorders. J Formos Med Assoc 2009; 108:353-66.

13. Орлова Е. А. Анализ нитритов и нитратов в ткани при экспериментальной острой почечной недостаточности. Укр журн экстремальной мед 2002; 1(3):79-82.

14. Thompson P. D., Buchner D., Piña I. L., et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the council on clinical cardiology (subcommittee on exercise, rehabilitation, and prevention) and the council on nutrition, physical activity, and metabolism (subcommittee on physical activity). Circulation 2003; 107(24):3109-16.

15. Grundy S. M., Hansen B., Smith S. C., Cleeman J. I., Kahn R. A. American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109(4):551-6.

16. Ивашкин В. Т., Маевская М. В. Липотоксичность и метаболические нарушения при ожирении. Рос журн гастроэнтерол гепатол колопроктол 2010; 20(1):4-13.

17. Kuboki K., Jiang Z. Y., Takahara N., Ha S. W., et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000; 101(6):6768.

18. Bełtowski J. Leptin and the regulation of endothelial function in physiological and pathological conditions. Clin Exp Pharmacol Physiol 2012; 39(2):168-78. 19. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014; 2014:943162.

19. Wang J., Wang H., Luo W., Guo C., et al. Leptininduced endothelial dysfunction is mediated by sympathetic nervous system activity. J Am Heart Assoc 2013; 2(5):000299.